Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer

Hormones and Cancer

Volumn 3, Issue 3, 2012, Pages 93-100

  Navaratnam, Sri ^a,c   Skliris, Georgios ^a,b   Qing, Gefei ^a   Banerji, Shantanu ^a,c   Badiani, Ketan ^b,c   Tu, Dongsheng ^d   Bradbury, Penelope A ^d   Leighl, Natasha B ^e   Shepherd, Frances A ^e   Nowatzki, Janet ^c   Demers, Alain ^c   Murphy, Leigh ^a,b,c,f  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CANCERCARE MANITOBA   (Canada)

^d Clinical Trials Group   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Clinical outcome; Estrogen receptor beta variants; Immunohistochemistry; Lung cancer; Sex; Tissue micro arrays

Indexed keywords

CARBOPLATIN; CASPASE 3; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53; REBIMASTAT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COHORT ANALYSIS; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEX DIFFERENCE; TISSUE MICROARRAY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84860582741     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0105-y     Document Type: Article

References (45)

1. Thomas L, Doyle L, Edelman M (2005) Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 128: 370-381.
2. Gasperino J, Rom W (2004) Gender and lung cancer. Clin Lung Cancer 5: 353-359.
3. Patel J (2005) Lung cancer in women. J Clin Oncol 23: 3212-3218.
4. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R et al (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol 21: 847-852.
5. Wheatley-Price P, Le Maitre A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA (2010) The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Oncol 5(5): 640-648.
6. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S et al. (2011) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. doi: 10. 1016/j. lungcan. 2011. 11. 008.
7. Patrone C, Cassel T, Pettersson K, Piao Y, Cheng G, Ciana P, Maggi A, Warner M, Gustafsson J, Nord M (2003) Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 23: 8542-8552.
8. Dougherty S, Mazhawidza W, Bohn A, Robinson K, Mattingly K, Blankenship K, Huff M, McGregor W, Klinge C (2006) Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. Endocr Relat Cancer 13: 113-134.
9. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, Moriya T, Hayashi S, Handa M, Kondo T et al (2005) Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65: 6450-6458.
10. Wu C, Chang Y, Shih J, Lee Y (2005) The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130: 979-986.
11. Stabile L, Davis A, Gubish C, Hopkins T, Luketich J, Christie N, Finkelstein S, Siegfried J (2002) Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150.
12. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y et al (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285: 340-347.
13. Pietras R, Marquez D, Chen H, Tsai E, Weinberg O, Fishbein M (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381.
14. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J (2005) Estrogen receptor A and B are prognostic factors in non small cell lung cancer. Clin Cancer Res 11: 5084-5089.
15. Murphy L, Watson P (2006) Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13: 327-334.
16. Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson J (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62(17): 4849-4853.
17. Fuqua S, Schiff R, Parra I, Friedrichs W, Su J, McKee D, Slentz-Kesler K, Moore L, Willson T, Moore J (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59: 5425-5428.
18. Peng B, Lu B, Leygue E, Murphy L (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30: 13-29.
19. Saji S, Omoto Y, Shimizu C, Horiguchi S, Watanabe T, Funata N, Hayash S, Gustafsson J, Toi M (2002) Clinical impact of assay of estrogen receptor beta cx in breast cancer. Breast Cancer Res Treat 9: 303-307.
20. Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S et al (2010) Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 41(2): 190-198.
21. Weinberg O, Marquez-Garban D, Fishbein M, Goodglick L, Garban H, Dubinett S, Pietras R (2005) Aromatase inhibitors in human lung cancer therapy. Cancer Res 65: 11287-11291.
22. Mauri D, Pavlidis N, Polyzos N, Ioannidis J (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98: 1285-1291.
23. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM (2009) Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64(1): 51-59.
24. Stabile L, Lyker J, Gubish C, Zhang W, Grandis J, Siegfried J (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65: 1459-1470.
25. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J et al (2005) Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 23(12): 2831-2839.
26. Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95: 616-626.
27. Murphy LC, Cherlet T, Adeyinka A, Niu Y, Snell L, Watson P (2004) Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo. Clin Cancer Res 10: 1354-1359.
28. Weitsman G, Skliris G, Ung K, Peng B, Younes M, Watson P, Murphy L (2006) Assessment of multiple different oestrogen receptor b antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 100: 23-31.
29. Skliris G, Parkes A, Limer J, Burdall S, Carder P, Speirs V (2002) Evaluation of seven oestrogen receptor b antibodies for immunohistochemistry, western blotting and flow cytometry in human breast tissue. J Pathol 197: 155-162.
30. Leav I, Lau K-M, Adams J, McNeal J, Taplin M-E, Wang J, Singh H, Ho S-M (2001) Comparative studies of the estrogen receptor b and a and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am J Pathol 159(1): 79-92.
31. Siegfried JM, Hershberger PA, Stabile LP (2009) Estrogen receptor signaling in lung cancer. Semin Oncol 36(6): 524-531.
32. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S (2005) Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 11(20): 7280-7287.
33. Skov BG, Fischer BM, Pappot H (2008) Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59(1): 88-94.
34. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C et al (2009) Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17): 5359-5368.
35. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson J, Iwase H (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38(3): 380-386.
36. Palmieri C, Lam E, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson J et al (2004) The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10(7): 2421-2428.
37. Leung Y, Mak P, Hassan S, Ho S (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103: 13162-13167.
38. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT et al (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16): 5228-5235.
39. Moore J, McKee D, Slentz-Kesler K, Moore L, Jones S, Horne E, Su J-L, Kliewer S, Lehmann' J, Willson T (1998) Cloning and characterization of human estrogen receptor b isoforms. Biochem Biophys Res Commun 247: 75-78.
40. Ali G, Donati V, Loggini B, Servadio A, Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A et al (2008) Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 39(10): 1465-1473.
41. Kelly RJ, Morris JC (2010) Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 7: 15-26.
42. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10): 4831-4842.
43. Skliris G, leygue E, Watson P, Murphy L (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109: 1-10.
44. Savinov A, Remacle A, Golubkov V, Krajewska M, Kennedy S, Duffy M, Rozanov D, Krajewski S, Strongin A (2006) Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res 66: 2716-2724.
45. Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S et al (2006) Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26: 7966-7976.